Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Ittai B. Muller, Adrianus J. De Langen, Richard J. Honeywell, Elisa Giovannetti, Godefridus J. Peters

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)147-157
JournalExpert Review of Anticancer Therapy
Issue number2
Publication statusPublished - 1 Feb 2016

Cite this